Relapsed and/or Refractory Multiple Myeloma
Conditions
Brief summary
The main thing the researchers are looking at is called "progression-free survival" (“PFS”). This means the time from when a person starts the treatment to when their cancer gets worse, or they die from any cause
Detailed description
They will also look at how long people live overall, which is called “overall survival” ("OS")., The researchers will also look at other things to see how well the treatment works. These include how well the cancer responds to the treatment, how long the cancer responds, and how long it takes for people to start a new treatment., They will also look at any side effects people have while taking the treatment and how it affects their quality of life., Overall, the researchers want to see if alnuctamab is a safe and effective treatment for people with multiple myeloma.
Interventions
DRUGDARZALEX 1800 mg solution for injection
DRUGAlnuctamab
DRUGImnovid 2 mg hard capsules
DRUGImnovid 3 mg hard capsules
DRUGImnovid 1 mg hard capsules
DRUGKyprolis 60 mg powder for solution for infusion
DRUGDEXAMETHASONE
DRUGImnovid 4 mg hard capsules
Sponsors
Celgene International II S.a.r.l.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main thing the researchers are looking at is called "progression-free survival" (“PFS”). This means the time from when a person starts the treatment to when their cancer gets worse, or they die from any cause | — |
Secondary
| Measure | Time frame |
|---|---|
| They will also look at how long people live overall, which is called “overall survival” ("OS")., The researchers will also look at other things to see how well the treatment works. These include how well the cancer responds to the treatment, how long the cancer responds, and how long it takes for people to start a new treatment., They will also look at any side effects people have while taking the treatment and how it affects their quality of life., Overall, the researchers want to see if alnuctamab is a safe and effective treatment for people with multiple myeloma. | — |
Countries
Austria, Belgium, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Norway, Portugal, Romania, Spain, Sweden
Outcome results
None listed